{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000029","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.427916+00:00","generated_at":"2026-05-23T05:04:00.584670+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025","bullets":["EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.","Flexible dosing: at home or healthcare setting; patient/caregiver administration if appropriate.","First corrective medicine for DEB in Europe; launch in Germany mid-2025; 1,000 DEB patients identified in France and Germany."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000029","json":"https://secwatch.observer/filing/0001711279-25-000029.json","markdown":"https://secwatch.observer/filing/0001711279-25-000029.md","text":"https://secwatch.observer/filing/0001711279-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/0001711279-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/krys-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:04:00.584670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}